Medpace (MEDP) 10-Q 31 Oct 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 27, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	MEDP
Entity Registrant Name	Medpace Holdings, Inc.
Entity Central Index Key	1,668,397
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		37,606,244

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 24,168	$ 37,099
Restricted cash	79	308
Accounts receivable and unbilled, net (includes $0.8 million and $2.3 million with related parties at September 30, 2017 and December 31, 2016, respectively)	74,708	79,767
Prepaid expenses and other current assets	18,074	16,074
Total current assets	117,029	133,248
Property and equipment, net	45,903	43,805
Goodwill	660,981	660,981
Intangible assets, net	108,234	136,071
Deferred income taxes	11,115	97
Other assets	5,614	4,903
Total assets	948,876	979,105
Current liabilities:
Accounts payable	9,972	10,911
Accrued expenses	20,085	24,417
Pre-funded study costs (includes $1.5 million and $3.9 million with related parties at September 30, 2017 and December 31, 2016, respectively)	53,246	51,948
Advanced billings (includes $2.7 million and $7.6 million with related parties at September 30, 2017 and December 31, 2016, respectively)	68,341	65,668
Current portion of long-term debt	15,469	12,375
Other current liabilities	5,250	3,284
Total current liabilities	172,363	168,603
Long-term debt, net, less current portion	169,152	151,267
Deemed landlord liability, less current portion	27,104	28,527
Deferred income tax liability	513	12,030
Deferred credit	20,956
Other long-term liabilities	8,538	7,968
Total liabilities	398,626	368,395
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively
Common stock - $0.01 par-value; 250,000,000 shares authorized at September 30, 2017 and December 31, 2016, respectively; 37,403,764 and 40,662,856 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	375	407
Additional paid-in capital	628,558	623,629
Accumulated deficit	(77,420)	(9,584)
Accumulated other comprehensive loss	(1,263)	(3,742)
Total shareholders’ equity	550,250	610,710
Total liabilities and shareholders’ equity	$ 948,876	$ 979,105

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable and unbilled, net with related parties	$ 0.8	$ 2.3
Pre-funded study costs with related parties	1.5	3.9
Advanced billings with related parties	$ 2.7	$ 7.6
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock shares authorized	250,000,000	250,000,000
Common stock shares issued	37,403,764	40,662,856
Common stock shares outstanding	37,403,764	40,662,856

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Service revenue, net (includes $2.0 million and $6.9 million with related parties for the three months ended September 30, 2017 and 2016, respectively, and $8.9 million and $19.3 million with related parties for the nine months ended September 30, 2017 and 2016, respectively)	$ 98,681	$ 94,812	$ 287,014	$ 275,245
Reimbursed out-of-pocket revenue (includes $0.2 million and $1.4 million with related parties for the three months ended September 30, 2017 and 2016, respectively, and $1.3 million and $4.3 million with related parties for the nine months ended September 30, 2017 and 2016, respectively)	11,962	12,987	36,456	38,094
Total revenue	110,643	107,799	323,470	313,339
Operating expenses:
Direct costs, excluding depreciation and amortization	53,144	51,221	156,204	147,436
Reimbursed out-of-pocket expenses (includes $0.2 million and $1.4 million with related parties for the three months ended September 30, 2017 and 2016, respectively, and $1.3 million and $4.3 million with related parties for the nine months ended September 30, 2017 and 2016, respectively)	11,962	12,987	36,456	38,094
Selling, general and administrative	16,606	16,391	46,515	44,724
Depreciation	2,237	1,915	6,468	5,481
Amortization	9,496	12,668	28,406	38,004
Total operating expenses	93,445	95,182	274,049	273,739
Income from operations	17,198	12,617	49,421	39,600
Other expense, net:
Miscellaneous expense, net	(145)	(378)	(642)	(1,319)
Interest expense, net	(1,906)	(4,656)	(5,508)	(16,550)
Total other expense, net	(2,051)	(5,034)	(6,150)	(17,869)
Income before income taxes	15,147	7,583	43,271	21,731
Income tax provision	5,316	2,547	15,440	8,285
Net income	$ 9,831	$ 5,036	$ 27,831	$ 13,446
Net income per share attributable to common shareholders:
Basic	$ 0.25	$ 0.14	$ 0.70	$ 0.39
Diluted	$ 0.25	$ 0.13	$ 0.69	$ 0.39
Weighted average common shares outstanding:
Basic	38,579	37,118	39,803	34,138
Diluted	39,329	37,623	40,537	34,365

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Service revenue with related parties	$ 2	$ 6.9	$ 8.9	$ 19.3
Reimbursed out-of-pocket revenue with related parties	0.2	1.4	1.3	4.3
Reimbursed out-of-pocket expenses with related parties	$ 0.2	$ 1.4	$ 1.3	$ 4.3

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 9,831	$ 5,036	$ 27,831	$ 13,446
Other comprehensive income
Foreign currency translation adjustments, net of taxes	765	176	2,479	184
Comprehensive income	$ 10,596	$ 5,212	$ 30,310	$ 13,630

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 27,831	$ 13,446
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	6,468	5,481
Amortization	28,406	38,004
Stock-based compensation expense	3,215	8,559
Amortization of debt issuance costs and discount	498	2,024
Deferred income tax benefit	(420)	(568)
Other	(615)	(256)
Changes in assets and liabilities:
Accounts receivable and unbilled, net	5,340	(16,606)
Prepaid expenses and other current assets	(1,271)	(8,733)
Accounts payable	(467)	(943)
Accrued expenses	(4,840)	1,257
Pre-funded study costs	1,149	6,810
Advanced billings	2,381	16,560
Other assets and liabilities, net	1,058	(2,368)
Net cash provided by operating activities	68,733	62,667
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures	(8,329)	(7,843)
Acquisition of intangibles	(569)	0
Other	44	83
Net cash used in investing activities	(8,854)	(7,760)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for common stock issuance costs	0	(2,719)
Proceeds from stock option exercises	1,187	452
Repurchases of common stock	(95,260)	0
Payment of debt	(9,281)	(225,054)
Proceeds from revolving loan	40,000	0
Payments on revolving loan	(10,000)	0
Payment of deemed landlord liability	(1,240)	(1,129)
Proceeds from common stock issued, net of underwriters discount	0	173,578
Net cash used in financing activities	(74,594)	(54,872)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	1,555	227
(DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(13,160)	262
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	37,407	17,737
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	$ 24,247	$ 17,999

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	(1) Basis of Presentation Description of Business Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Unaudited Interim Financial Information The interim condensed consolidated financial statements include the accounts of the Company, are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), and are unaudited. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The preparation of the interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results and outcomes could differ from management’s estimates and assumptions. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 Share Repurchases In August 2017, the Board of Directors of the Company (the “Board”) members who are not affiliated with Cinven (the “Disinterested Directors”) approved a stock repurchase agreement with Medpace Limited Partnership, a Guernsey limited partnership (the “Limited Partnership” acting through its general partner, Medpace GP Limited, a Guernsey company, the “General Partner” and, the Limited Partnership acting through the General Partner, “Cinven”), pursuant to which the Company repurchased 2,000,000 shares of the Company’s common stock from Cinven for aggregate consideration of approximately $60.5 million, representing a purchase price of $30.27 per share. The Company funded the repurchase with cash on hand and $40.0 million in borrowings under the Senior Secured Revolving Credit Facility. In April 2017, the Board of the Company authorized a share repurchase program with an authorized repurchase level of $50.0 million. The share repurchase program, according to its terms, will expire in April 2018. Repurchases under the repurchase program may take place in the open market or negotiated transactions, at the discretion of the Company’s management The Company has elected to constructively retire all repurchased shares with all amounts paid in excess of Common stock par value reflected within Accumulated deficit in the Company’s condensed consolidated balance sheets. Recently Adopted Accounting Standards In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-01, Business Combinations. The standard changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. Under the new guidance, an entity first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the set is not a business. If it’s not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. The Company, as permitted, early adopted ASU 2017-01 using the prospective method in the second quarter of 2017. ASU 2017-01 was considered in the asset acquisition described in Note 2. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance is intended to reduce diversity in practice by requiring the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash and restricted cash equivalents. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. The Company, as permitted, early adopted ASU 2016-18 in the fourth quarter of 2016. As a result of this adoption, cash flows resulting from changes in restricted cash balances, are no longer presented as a component of net cash provided by operating activities in the Company’s condensed consolidated statements of cash flows, but have been reclassified and combined within (Decreases)/Increases in Cash, Cash Equivalents and Restricted Cash. This reclassification was retrospectively applied to all periods presented within the condensed consolidated statements of cash flows. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting • Income taxes - Upon adoption of this standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends, if distributed, on share-based payment awards) are recognized as income tax expense or benefit in the statement of operations. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. As a result, the Company recognized discrete adjustments to income tax expense for the nine months ended September 30, 2017 of less than $0.1 million related to excess tax benefits. The Company also recognizes excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. The Company applied the prospective adoption approach for any unrecognized excess tax benefits beginning in 2017, which did not result in any cumulative-effect adjustment upon adoption. Prior periods have not been adjusted. • Forfeitures - Prior to adoption, share-based compensation expense was recognized on a straight line basis, net of estimated forfeitures, such that expense was recognized only for share-based awards that were expected to vest. A forfeiture rate was estimated annually and revised, if necessary, in subsequent periods if actual forfeitures differed from initial estimates. Upon adoption, the Company no longer applies a forfeiture rate and instead accounts for forfeitures as they occur. The Company applied the modified retrospective adoption approach beginning in 2017 and booked an immaterial cumulative-effect adjustment to additional paid-in-capital and retained earnings within Shareholders’ Equity. Prior periods have not been adjusted. • Statements of Cash Flows - The Company historically accounted for excess tax benefits on the condensed consolidated statements of cash flows as a financing activity. Upon adoption of this standard, excess tax benefits are classified along with other income tax cash flows as an operating activity. The Company elected to adopt this portion of the standard on a prospective basis beginning in 2017. Prior periods have not been adjusted. • Earnings Per Share - The Company uses the treasury stock method to compute diluted earnings per share, unless the effect would be anti-dilutive. Under this method, the Company is no longer required to estimate the tax rate and apply it to the dilutive share calculation for determining the dilutive earnings per share. The Company utilized the prospective adoption approach and applied this methodology beginning in 2017. Prior periods have not been adjusted. Upon adoption, no other aspects of ASU 2016-09 had an effect on the Company's condensed consolidated financial statements or related footnote disclosures. Recently Issued Accounting Standards In February 2016, the FASB issued ASU 2016-02, (Topic 842). Leases (FAS 13) In May 2014, the FASB issued ASU No. 2014-09 ‘‘Revenue from Contracts with Customers,’’ to clarify the principles of recognizing revenue and create common revenue recognition guidance between US GAAP and International Financial Reporting Standards. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. In December 2016, the FASB issued ASU 2016-20 Technical Corrections and Improvements to Topic 606, Revenue From Contracts with Customers. ASUs’ 2016-20, 2016-12, 2016-10 and 2016-08 all clarify the interpretation guidance in ASU No. 2014-09, “Revenue from Contracts with Customers” specifically related to narrowing specific aspects of Topic 606 and adding illustrative examples to assist in the application of the guidance. The effective date and transition requirements in ASUs’ 2016-20, 2016-12, 2016-10, and 2016-08 are the same as the effective date and transition requirements of ASU 2014-09. ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, deferred the original effective date of ASU 2014-09 by one year. The new standard allows for either a retrospective or modified retrospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company continues to evaluate the potential impact of adopting this standard on its business policies, processes and systems, internal control over financial reporting environment, and financial reporting disclosures. The Company expects that the majority of its contracts will have a single performance obligation that is satisfied over time, with revenue recognized based on overall project progress measured as of the financial statement date. This represents a change in the Company’s current revenue accounting methodology as a majority of contracts are accounted for with multiple units of account under the multiple element arrangement guidance. Under the current accounting methodology, certain revenue related to reimbursable expenses is presented either as a separate line item within Reimbursable out-of-pocket revenue or net of related expenses within Service revenue, net in the condensed consolidated statements of operations. As a result of having a single performance obligation, the Company anticipates that all revenue related to reimbursable expenses will prospectively be accounted for gross within a single revenue line item with related expenses presented gross within Direct Costs, excluding depreciation and amortization. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company will adopt ASU 2014-09 as well as the clarified guidance in ASUs’ 2016-20, 2016-12, 2016-10, 2016-08, utilizing the modified retrospective approach, during the first quarter of 2018.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2017
Asset Acquisition [Abstract]
Acquisition	(2) Acquisition In May 2017, the Company acquired out of bankruptcy NephroGenex, Inc. (“Nephrogenex” or the “Debtor”), a publicly-held pharmaceutical company that had previously filed for relief under Chapter 11 of the United States Bankruptcy Code. The Company, which was the largest unsecured creditor of Nephrogenex, entered into an agreement through the bankruptcy process, to exchange its unsecured claim for 100% of the common stock in the post-bankruptcy, debt free Debtor. The assets of the acquired Debtor consist primarily of tax attributes as well as in-process research and development and other intangible assets. An analysis by the Company determined that substantially all the fair value of the assets on the date of acquisition is captured in the tax attributes, as the intangible assets account for a relatively immaterial portion of the fair market value of the total assets received. The acquisition of the Debtor was accounted for as an asset purchase. The Company allocated its consideration paid of $1.2 million, consisting of accounts receivable and unbilled receivables and transaction related costs, on a pro rata basis to the assets acquired based on their respective fair values. Acquired assets include intangible assets of $0.5 million, deferred tax assets of $22.2 million, consisting of tax effected net operating losses in the amount of $21.1 (partially offset with a $7.6 million valuation allowance), tax effected capitalized research and development expenses of $8.5 million and tax effected federal tax credits of $1.4 million (partially offset with a $1.2 million valuation allowance) and deferred tax liabilities of $0.1 million. The excess amount of fair value received over consideration paid of $21.4 million was recorded as a Deferred credit in the condensed consolidated balance sheets and will be recognized within Income tax provision in proportion to the realization of the deferred tax assets and federal tax credits prospectively.

Net Income Per Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Income Per Share	(3) Net Income Per Share Basic and diluted earnings or loss per share (“EPS”) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. Restricted Stock Awards (“RSAs”) are considered participating securities because they are legally issued at the date of grant and holders are entitled to receive non-forfeitable dividends during the vesting term. The computation of diluted EPS includes additional common shares, such as unvested stock options with exercise prices less than the average market price of the Company’s common stock during the period (“in-the-money options”), which would be considered outstanding under the treasury stock method. The treasury stock method assumes that additional shares would have to be issued in cases where the exercise price of stock options is less than the value of the common stock being acquired because the cash proceeds received from the stock option holder would not be sufficient to acquire that same number of shares. The Company does not compute diluted EPS in cases where the inclusion of such additional shares would be anti-dilutive in effect. The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2017 and 2016, (in thousands, except for earnings per share): Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Weighted-average shares: Common shares outstanding 38,579 37,118 39,803 34,138 RSAs 62 - 60 - Total weighted-average shares 38,641 37,118 39,863 34,138 Earnings per common share—Basic Net income $ 9,831 $ 5,036 $ 27,831 $ 13,446 Less: Undistributed earnings allocated to RSAs 16 - 42 - Net income available to common shareholders—Basic $ 9,815 $ 5,036 $ 27,789 $ 13,446 Net income per common share—Basic $ 0.25 $ 0.14 $ 0.70 $ 0.39 Basic weighted-average common shares outstanding 38,579 37,118 39,803 34,138 Effect of diluted shares 750 505 734 227 Diluted weighted-average shares outstanding 39,329 37,623 40,537 34,365 Net income per common share—Diluted $ 0.25 $ 0.13 $ 0.69 $ 0.39 During the three months ended September 30, 2017 and 2016, respectively, there were 158,034 and 61,896 shares excluded from the computation of EPS because they were anti-dilutive under the treasury method calculation of diluted weighted average shares outstanding. During the nine months ended September 30, 2017 and 2016, respectively, there were 90,553 and 25,699 shares excluded from the computation of EPS because they were anti-dilutive under the treasury method calculation of diluted weighted average shares outstanding. During the three months ended September 30, 2017, there were 27,500 stock options that were excluded from the computation of EPS due to the exercise price exceeding the average fair value of the Company’s common stock during the period. During the nine months ended September 30, 2017 and 2016, respectively, there were 27,500 and 643,680 stock options that were excluded from the computation of EPS due to the exercise price exceeding the average fair value of the Company’s common stock during the period.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	(4) Fair Value Measurements The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities. Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data. Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities. The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses and advanced billings approximate their carrying amounts due to their short term maturities. The Company does not have any recurring fair value measurements as of September 30, 2017. There were no transfers between Level 1, Level 2 or Level 3 during the three or nine months ended September 30, 2017 and 2016.

Accounts Receivable And Unbille

Accounts Receivable And Unbilled, Net	9 Months Ended
	Sep. 30, 2017
Receivables [Abstract]
Accounts Receivable And Unbilled, Net	(5) Accounts Receivable And Unbilled, Net Accounts receivable and unbilled, net includes service revenue and reimbursed out-of-pocket revenue. Accounts receivable and unbilled, net consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Accounts receivable $ 50,973 $ 48,270 Unbilled 25,947 34,719 Less allowance for doubtful accounts (2,212) (3,222) Total accounts receivable and unbilled, net $ 74,708 $ 79,767

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	(6) Intangible Assets, Net Intangible assets, net consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Intangible assets: Finite-lived intangible assets: Carrying amount: Backlog $ 72,630 $ 72,630 Customer relationships 145,051 145,051 Developed technologies 54,475 54,475 Other 3,074 2,505 Total finite-lived intangible assets 275,230 274,661 Accumulated amortization: Backlog (72,630 ) (72,630 ) Customer relationships (86,063 ) (66,267 ) Developed technologies (38,133 ) (29,961 ) Other (1,816 ) (1,378 ) Total accumulated amortization (198,642 ) (170,236 ) Total finite-lived intangible assets, net 76,588 104,425 Trade name (indefinite-lived) 31,646 31,646 Total intangible assets, net $ 108,234 $ 136,071 As of September 30, 2017, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands): Amortization Remainder of 2017 $ 9,495 2018 29,561 2019 14,828 2020 7,877 2021 5,114 Later years 9,713 $ 76,588

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2017
Payables And Accruals [Abstract]
Accrued Expenses	(7) Accrued Expenses Accrued expenses consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Employee compensation and benefits $ 16,989 $ 21,453 Other 3,096 2,964 Total accrued expenses $ 20,085 $ 24,417

Debt

Debt	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt	(8) Debt Debt consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Revolving credit facility $ 30,000 $ - Term loan 155,719 165,000 Less unamortized discount (432 ) (534 ) Less unamortized term loan debt issuance costs (666 ) (824 ) Less current portion of long-term debt (15,469 ) (12,375 ) Long-term debt, net, less current portion $ 169,152 $ 151,267 Principal payments on debt are due as follows (in thousands): 2017 (remaining) $ 3,094 2018 16,500 2019 16,500 2020 20,625 2021 129,000 Total $ 185,719 The estimated fair value of the Company’s debt based on Level 2 inputs using the market approach, which is primarily based on rates at which the debt is traded among financial institutions, approximates the carrying value as of September 30, 2017 and December 31, 2016.

Shareholder's Equity and Stock-

Shareholder's Equity and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shareholder's Equity and Stock-Based Compensation	(9) Shareholder’s Equity and Stock-Based Compensation The Company granted 974,896 awards to employees under the 2016 Incentive Award Plan, during the nine months ended September 30, 2017, consisting of 777,550 stock option awards, 118,000 restricted stock awards (“RSA”) and 38,000 restricted stock units (“RSU”), all vesting after four years. The Company granted an additional 41,346 stock option awards, vesting over one year, to non-employee directors under the 2016 Incentive Award Plan, during the nine months ended September 30, 2017. The Company granted 45,923 Awards under the 2014 Equity Incentive Plan, consisting of 34,812 stock options vesting equally over four years and 11,111 fully-vested shares, during the nine months ended September 30, 2016. The Company also granted 643,680 stock options under the 2016 Plan during the nine months ended September 30, 2016, consisting of 626,650 stock options vesting after four years and 17,030 stock options with one-third vesting on October 31, 2016, and the remainder vesting in eight equal monthly installments beginning in November 2016. Award Activity The following table sets forth the Company’s stock option activity: Nine Months Ended September 30, 2017 Weighted Stock Options Exercise Price Outstanding - beginning of period 2,350,166 $ 17.57 Granted 818,896 $ 28.29 Exercised (83,675 ) $ 15.26 Forfeited/Expired (225,051 ) $ 20.66 Outstanding - end of period 2,860,336 $ 20.46 Exercisable - end of period 939,835 $ 15.34 The following table sets forth the Company’s RSA/RSU activity: Nine Months Ended September 30, 2017 Shares/Units Outstanding and unvested - beginning of period 59,258 Granted 156,000 Vested - Forfeited - Outstanding and unvested - end of period 215,258 Cumulative vested shares - end of period 1,854,658 Stock-based compensation expense recognized in the condensed consolidated statements of operations related to all outstanding stock based compensation awards is summarized below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Direct costs, excluding depreciation and amortization $ 389 $ 2,500 $ 1,504 $ 4,974 Selling, general and administrative 592 1,784 1,711 3,585 Total stock-based compensation expense $ 981 $ 4,284 $ 3,215 $ 8,559

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(10) Income Taxes The Company’s effective income tax rate was 35.1% and 35.7% for the three and nine months ended September 30, 2017, respectively. The Company’s effective income tax rate was 33.6% and 38.1% for the three and nine months ended September 30, 2016, respectively. The Company’s effective income tax rate for the three and nine months ended September 30, 2017 varied from the U.S. statutory rate of 35.0% primarily due to the impact of state taxes, domestic and foreign uncertain tax positions and the tax impact associated with acquired tax attributes.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(11) Commitments and Contingencies Legal Proceedings The Company is involved in legal proceedings from time to time in the ordinary course of its business, including employment claims and claims related to other business transactions. The Company cannot predict with certainty the outcome of such proceedings, but it believes that adequate reserves have been recorded and losses already recognized with respect to such actions were immaterial as of September 30, 2017 and December 31, 2016. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, the Company believes that such potential losses were immaterial as of September 30, 2017.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	(12) Related Party Transactions Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commencement of employment. Total receivables as a result of these employee advances of $0.2 million existed at September 30, 2017 and December 31, 2016, respectively, and are included in the Prepaid expenses and other current assets and Other assets line items of the condensed consolidated balance sheets, respectively, depending on the contractual repayment date. Management Fees The Company pays fees for director services provided by Cinven employees that are members of the Company’s Board of Directors and any related committees. The director fees are paid directly to Cinven in accordance with the Company’s non-employee director compensation policy. During the three and nine months ended September 30, 2017, the Company incurred board of director fees to Cinven of less than $0.1 million and $0.1 million, respectively, in the Company’s condensed consolidated statement of operations. During the three and nine months ended September 30, 2016, the Company incurred management fees to Cinven of less than $0.1 million and $0.2 million, respectively, in the Company’s condensed consolidated statements of operations. Service Agreements Symplmed Pharmaceuticals, LLC (“Symplmed”) Medpace Investors LLC, a noncontrolling shareholder of the Company that is owned by employees of the Company and managed by the Company’s chief executive officer, has a majority ownership interest in Symplmed, a private pharmaceutical development company. In addition, the chief executive officer and other executives of the Company are board members of Symplmed. The Company has operated under a Master Services Agreement (“MSA”) with Symplmed since 2013 (amended in 2014) to perform clinical trial related services. Certain task orders governed by this arrangement were amended in the third quarter of 2016, changing the fee structure from unitized in nature to time and materials and revised pricing to more appropriately reflect market pricing based on the Company’s leveraging of this work to develop and enhance certain new service capabilities. The Company has evaluated its relationship with Symplmed and concluded that Symplmed is not a variable interest entity because the Company has no direct ownership interest or relationship other than the MSA. During the three months ended September 30, 2017 and 2016, the Company recognized service revenue from Symplmed of less than $0.1 million and negative service revenue adjustments from Symplmed of $0.4 million, respectively, and during the nine months ended September 30, 2017 and 2016, the Company recognized service revenue from Symplmed of less than $0.1 million and negative service revenue adjustments from Symplmed of less than $0.1 million, respectively, in the Company’s condensed consolidated statements of operations. Coherus BioSciences, Inc. (“Coherus”) The chief executive officer of the Company is a member of Coherus’s board of directors. During the three months ended September 30, 2017 and 2016, the Company recognized service revenue from Coherus of $1.4 million and $6.8 million, respectively, and during the nine months ended September 30, 2017 and 2016, the Company recognized service revenue from Coherus of $6.5 million and $18.2 million, respectively, in the Company’s condensed consolidated statements of operations. In addition, the company recognized Reimbursed out-of-pocket revenue and Reimbursed out-of-pocket expenses with Coherus in the condensed consolidated statements of operations of $ million and $ million during the three months ended September 30, 2017 and 2016, respectively, and $ million and $ million during the nine months ended September 30, 2017 and 2016. Xenon Pharmaceuticals, Inc. (“Xenon”) Certain executives and employees of the Company, including the chief executive officer, have held equity investments in Xenon, a clinical-stage biopharmaceutical company. During the second quarter of 2017, the chief executive officer sold his entire equity position held in Xenon. Xenon is no longer considered to be a related party subsequent to this sale. During July 2015 the Company and Xenon entered into an amended MSA agreement for the Company to provide clinical trial related services. The Company recognized service revenue from Xenon of $0.4 million during the three months ended September 30, 2016, and service revenue from Xenon of $0.6 million and $0.8 million during the six months ended June 30, 2017 and nine months ended September 30, 2016, respectively, in the Company’s condensed consolidated statements of operations. As of December 31, 2016, the Company had, from Xenon, $1.3 million of Advanced billings and $0.1 million of Pre-funded study costs in the condensed consolidated balance sheets. Cymabay Therapeutics, Inc. (“Cymabay”) Cymabay is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. During the first quarter of 2016, it was announced that a Medpace employee would join Cymabay’s board of directors. The Company and Cymabay entered into a MSA dated October 21, 2016. Subsequently, the Company and Cymabay have entered into several task orders for the Company to perform clinical trial related services. LIB Therapeutics LLC (“LIB”) Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. During the three months ended September 30, 2017 and 2016, the Company recognized service revenue from LIB of $0.5 million and $0.1 million, respectively, and during the nine months ended September 30, 2017 and 2016, the Company recognized service revenue from LIB of $1.1 million and $0.1 million, respectively, in the Company’s condensed consolidated statements of operations. As of September 30, 2017 and December 31, 2016, respectively, the Company had Accounts receivable and unbilled, net from LIB of $0.2 million and less than $0.1 million recorded in the condensed consolidated balance sheets. CinRx Pharma, LLC (“CinRx”) Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the three and nine months ended September 30, 2017, the Company recognized service revenue from CinRx of $0.1 million and $0.3 million, respectively, in the Company’s condensed consolidated statements of operations. Medpace Investors, LLC Medpace Investors is a noncontrolling shareholder and related party of Medpace Holdings, Inc. Medpace Investors is owned and managed by employees of the Company. The chief executive officer of Medpace is also the manager and majority unit holder of Medpace Investors. The Company acted as a paying agent for Medpace Investors with taxing authorities principally in instances when employee tax payments or remittance of withholdings related to equity compensation are required. During the three and nine months ended September 30, 2016, the Company paid $0.1 million and $0.8 million to various taxing authorities on behalf of Medpace Investors. Purchase of Real Estate Properties In December 2016, the Company entered into a purchase agreement for four parcels of real estate property that are closely situated to the Medpace campus in Cincinnati, Ohio, from AT Redevelopment Company, LLC, which is wholly-owned by the Company’s chief executive officer. The purchase price of the real estate property was $0.4 million as determined by an independent third party broker's opinion of value. The transaction closed on January 11, 2017. Leased Real Estate Headquarters Lease The Company entered into an operating lease for its corporate headquarters with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the lease. The lease for headquarters is for an initial term of twelve years through November 2022 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. Lease expense recognized for each of the three months ended September 30, 2017 and 2016 was $0.5 million, respectively, and lease expense recognized for each of the nine months ended September 30, 2017 and 2016 was $1.6 million, respectively. The lease expense was allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the condensed consolidated statements of operations. Deemed Assets and Deemed Landlord Liabilities The Company entered into two multi-year lease agreements governing the occupancy of space of two buildings in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. In accordance with the accounting guidance related to leases, the Company was deemed in substance to be the owner of the property during the construction phase and at completion. Accordingly, the Company reflected the buildings and related liabilities as deemed assets from landlord building construction in Property and equipment, net, Other current liabilities, and Deemed landlord liability, less current portion, respectively, on the condensed consolidated balance sheets. The Company assumed occupancy in 2012 and the leases expire in 2027 with the Company having one 10-year option to extend the lease term. The deemed assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease. Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties. Accretion expense is being recorded over the term of the lease as a component of Interest expense, net in the Company’s condensed consolidated statements of operations. The Company paid $0.9 million during the three months ended September 30, 2017 and 2016, respectively, and $2.8 million during the nine months ended September 30, 2017 and 2016. The current and long-term portions of the Deemed landlord liability at September 30, 2017 were $1.8 million and $27.1 million, respectively. The current and long-term portions of the Deemed landlord liability at December 31, 2016 were $1.7 million and $28.5 million, respectively. The Company has recognized deemed assets, net of $16.8 million and $18.1 million at September 30, 2017 and December 31, 2016, respectively, in the condensed consolidated balance sheets. Travel Services The Company incurs expenses for travel services for company executives provided by a private aviation charter company that is owned by the chief executive officer and the executive vice president of operations of the Company (“private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $0.3 million during the three months ended September 30, 2017 and 2016, respectively, and $0.9 million and $0.8 during the nine months ended September 30, 2017 and 2016, respectively, related to these travel services. These travel expenses are recorded in Selling, general and administrative in the Company’s condensed consolidated statements of operations.

Cash Flow Statement- Supplement

Cash Flow Statement- Supplemental Information	9 Months Ended
	Sep. 30, 2017
Supplemental Cash Flow Information [Abstract]
Cash Flow Statement- Supplemental Information	(13) Cash Flow Statement- Supplemental Information During the nine months ended September 30, 2017, the Company engaged in the following significant non-cash investing and financing activities: • Acquired net assets totaling $0.7 million consisting of net Deferred tax assets of $22.2 million, offset by net Deferred tax liabilities of $0.1 million and Deferred credits of $21.4 million in exchange for Accounts receivable and unbilled, net of $0.6 million and Other assets of $0.1 million.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The interim condensed consolidated financial statements include the accounts of the Company, are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), and are unaudited. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The preparation of the interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results and outcomes could differ from management’s estimates and assumptions. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016
Share Repurchases	Share Repurchases In August 2017, the Board of Directors of the Company (the “Board”) members who are not affiliated with Cinven (the “Disinterested Directors”) approved a stock repurchase agreement with Medpace Limited Partnership, a Guernsey limited partnership (the “Limited Partnership” acting through its general partner, Medpace GP Limited, a Guernsey company, the “General Partner” and, the Limited Partnership acting through the General Partner, “Cinven”), pursuant to which the Company repurchased 2,000,000 shares of the Company’s common stock from Cinven for aggregate consideration of approximately $60.5 million, representing a purchase price of $30.27 per share. The Company funded the repurchase with cash on hand and $40.0 million in borrowings under the Senior Secured Revolving Credit Facility. In April 2017, the Board of the Company authorized a share repurchase program with an authorized repurchase level of $50.0 million. The share repurchase program, according to its terms, will expire in April 2018. Repurchases under the repurchase program may take place in the open market or negotiated transactions, at the discretion of the Company’s management The Company has elected to constructively retire all repurchased shares with all amounts paid in excess of Common stock par value reflected within Accumulated deficit in the Company’s condensed consolidated balance sheets.
Recently Adopted and Issued Accounting Standards	Recently Adopted Accounting Standards In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-01, Business Combinations. The standard changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. Under the new guidance, an entity first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the set is not a business. If it’s not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. The Company, as permitted, early adopted ASU 2017-01 using the prospective method in the second quarter of 2017. ASU 2017-01 was considered in the asset acquisition described in Note 2. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance is intended to reduce diversity in practice by requiring the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash and restricted cash equivalents. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. The Company, as permitted, early adopted ASU 2016-18 in the fourth quarter of 2016. As a result of this adoption, cash flows resulting from changes in restricted cash balances, are no longer presented as a component of net cash provided by operating activities in the Company’s condensed consolidated statements of cash flows, but have been reclassified and combined within (Decreases)/Increases in Cash, Cash Equivalents and Restricted Cash. This reclassification was retrospectively applied to all periods presented within the condensed consolidated statements of cash flows. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting • Income taxes - Upon adoption of this standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends, if distributed, on share-based payment awards) are recognized as income tax expense or benefit in the statement of operations. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. As a result, the Company recognized discrete adjustments to income tax expense for the nine months ended September 30, 2017 of less than $0.1 million related to excess tax benefits. The Company also recognizes excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. The Company applied the prospective adoption approach for any unrecognized excess tax benefits beginning in 2017, which did not result in any cumulative-effect adjustment upon adoption. Prior periods have not been adjusted. • Forfeitures - Prior to adoption, share-based compensation expense was recognized on a straight line basis, net of estimated forfeitures, such that expense was recognized only for share-based awards that were expected to vest. A forfeiture rate was estimated annually and revised, if necessary, in subsequent periods if actual forfeitures differed from initial estimates. Upon adoption, the Company no longer applies a forfeiture rate and instead accounts for forfeitures as they occur. The Company applied the modified retrospective adoption approach beginning in 2017 and booked an immaterial cumulative-effect adjustment to additional paid-in-capital and retained earnings within Shareholders’ Equity. Prior periods have not been adjusted. • Statements of Cash Flows - The Company historically accounted for excess tax benefits on the condensed consolidated statements of cash flows as a financing activity. Upon adoption of this standard, excess tax benefits are classified along with other income tax cash flows as an operating activity. The Company elected to adopt this portion of the standard on a prospective basis beginning in 2017. Prior periods have not been adjusted. • Earnings Per Share - The Company uses the treasury stock method to compute diluted earnings per share, unless the effect would be anti-dilutive. Under this method, the Company is no longer required to estimate the tax rate and apply it to the dilutive share calculation for determining the dilutive earnings per share. The Company utilized the prospective adoption approach and applied this methodology beginning in 2017. Prior periods have not been adjusted. Upon adoption, no other aspects of ASU 2016-09 had an effect on the Company's condensed consolidated financial statements or related footnote disclosures. Recently Issued Accounting Standards In February 2016, the FASB issued ASU 2016-02, (Topic 842). Leases (FAS 13) In May 2014, the FASB issued ASU No. 2014-09 ‘‘Revenue from Contracts with Customers,’’ to clarify the principles of recognizing revenue and create common revenue recognition guidance between US GAAP and International Financial Reporting Standards. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. In December 2016, the FASB issued ASU 2016-20 Technical Corrections and Improvements to Topic 606, Revenue From Contracts with Customers. ASUs’ 2016-20, 2016-12, 2016-10 and 2016-08 all clarify the interpretation guidance in ASU No. 2014-09, “Revenue from Contracts with Customers” specifically related to narrowing specific aspects of Topic 606 and adding illustrative examples to assist in the application of the guidance. The effective date and transition requirements in ASUs’ 2016-20, 2016-12, 2016-10, and 2016-08 are the same as the effective date and transition requirements of ASU 2014-09. ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, deferred the original effective date of ASU 2014-09 by one year. The new standard allows for either a retrospective or modified retrospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company continues to evaluate the potential impact of adopting this standard on its business policies, processes and systems, internal control over financial reporting environment, and financial reporting disclosures. The Company expects that the majority of its contracts will have a single performance obligation that is satisfied over time, with revenue recognized based on overall project progress measured as of the financial statement date. This represents a change in the Company’s current revenue accounting methodology as a majority of contracts are accounted for with multiple units of account under the multiple element arrangement guidance. Under the current accounting methodology, certain revenue related to reimbursable expenses is presented either as a separate line item within Reimbursable out-of-pocket revenue or net of related expenses within Service revenue, net in the condensed consolidated statements of operations. As a result of having a single performance obligation, the Company anticipates that all revenue related to reimbursable expenses will prospectively be accounted for gross within a single revenue line item with related expenses presented gross within Direct Costs, excluding depreciation and amortization. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company will adopt ASU 2014-09 as well as the clarified guidance in ASUs’ 2016-20, 2016-12, 2016-10, 2016-08, utilizing the modified retrospective approach, during the first quarter of 2018.

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS	The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2017 and 2016, (in thousands, except for earnings per share): Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Weighted-average shares: Common shares outstanding 38,579 37,118 39,803 34,138 RSAs 62 - 60 - Total weighted-average shares 38,641 37,118 39,863 34,138 Earnings per common share—Basic Net income $ 9,831 $ 5,036 $ 27,831 $ 13,446 Less: Undistributed earnings allocated to RSAs 16 - 42 - Net income available to common shareholders—Basic $ 9,815 $ 5,036 $ 27,789 $ 13,446 Net income per common share—Basic $ 0.25 $ 0.14 $ 0.70 $ 0.39 Basic weighted-average common shares outstanding 38,579 37,118 39,803 34,138 Effect of diluted shares 750 505 734 227 Diluted weighted-average shares outstanding 39,329 37,623 40,537 34,365 Net income per common share—Diluted $ 0.25 $ 0.13 $ 0.69 $ 0.39

Accounts Receivable And Unbil23

Accounts Receivable And Unbilled, Net (Tables)	9 Months Ended
	Sep. 30, 2017
Receivables [Abstract]
Schedule of Accounts Receivable and Unbilled, Net	Accounts receivable and unbilled, net consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Accounts receivable $ 50,973 $ 48,270 Unbilled 25,947 34,719 Less allowance for doubtful accounts (2,212) (3,222) Total accounts receivable and unbilled, net $ 74,708 $ 79,767

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	Intangible assets, net consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Intangible assets: Finite-lived intangible assets: Carrying amount: Backlog $ 72,630 $ 72,630 Customer relationships 145,051 145,051 Developed technologies 54,475 54,475 Other 3,074 2,505 Total finite-lived intangible assets 275,230 274,661 Accumulated amortization: Backlog (72,630 ) (72,630 ) Customer relationships (86,063 ) (66,267 ) Developed technologies (38,133 ) (29,961 ) Other (1,816 ) (1,378 ) Total accumulated amortization (198,642 ) (170,236 ) Total finite-lived intangible assets, net 76,588 104,425 Trade name (indefinite-lived) 31,646 31,646 Total intangible assets, net $ 108,234 $ 136,071
Schedule of Estimated Amortization Expense of Intangible Assets	As of September 30, 2017, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands): Amortization Remainder of 2017 $ 9,495 2018 29,561 2019 14,828 2020 7,877 2021 5,114 Later years 9,713 $ 76,588

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2017
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Employee compensation and benefits $ 16,989 $ 21,453 Other 3,096 2,964 Total accrued expenses $ 20,085 $ 24,417

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Debt	Debt consisted of the following (in thousands): As of September 30, December 31, 2017 2016 Revolving credit facility $ 30,000 $ - Term loan 155,719 165,000 Less unamortized discount (432 ) (534 ) Less unamortized term loan debt issuance costs (666 ) (824 ) Less current portion of long-term debt (15,469 ) (12,375 ) Long-term debt, net, less current portion $ 169,152 $ 151,267
Schedule of Principal Payments on Debt Due	Principal payments on debt are due as follows (in thousands): 2017 (remaining) $ 3,094 2018 16,500 2019 16,500 2020 20,625 2021 129,000 Total $ 185,719

Shareholder's Equity and Stoc27

Shareholder's Equity and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table sets forth the Company’s stock option activity: Nine Months Ended September 30, 2017 Weighted Stock Options Exercise Price Outstanding - beginning of period 2,350,166 $ 17.57 Granted 818,896 $ 28.29 Exercised (83,675 ) $ 15.26 Forfeited/Expired (225,051 ) $ 20.66 Outstanding - end of period 2,860,336 $ 20.46 Exercisable - end of period 939,835 $ 15.34
Schedule of RSA/RSU Activity	The following table sets forth the Company’s RSA/RSU activity: Nine Months Ended September 30, 2017 Shares/Units Outstanding and unvested - beginning of period 59,258 Granted 156,000 Vested - Forfeited - Outstanding and unvested - end of period 215,258 Cumulative vested shares - end of period 1,854,658
Summary of Stock-Based Compensation Expense Recognized in Statements of Operations Related to All Outstanding Stock Based Compensation Awards	Stock-based compensation expense recognized in the condensed consolidated statements of operations related to all outstanding stock based compensation awards is summarized below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Direct costs, excluding depreciation and amortization $ 389 $ 2,500 $ 1,504 $ 4,974 Selling, general and administrative 592 1,784 1,711 3,585 Total stock-based compensation expense $ 981 $ 4,284 $ 3,215 $ 8,559

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Aug. 31, 2017	Apr. 30, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Basis Of Presentation [Line Items]
Repurchases of common stock, value				$ 95,260,000	$ 0
Share Repurchase Program
Basis Of Presentation [Line Items]
Repurchases of outstanding common stock, shares			300,331	1,342,786
Repurchases of common stock, value			$ 8,300,000	$ 34,700,000
Stock repurchase program, expiration date		2018-04
Senior Secured Revolving Credit Facility
Basis Of Presentation [Line Items]
Share repurchases funding through borrowings	$ 40,000,000
Cinven
Basis Of Presentation [Line Items]
Repurchases of outstanding common stock, shares	2,000,000
Repurchases of common stock, value	$ 60,500,000
Purchase price of repurchased shares	$ 30.27
Maximum
Basis Of Presentation [Line Items]
Stock repurchase program, authorized amount		$ 50,000,000
Maximum | Accounting Standard Update (“ASU”) No. 2016-09
Basis Of Presentation [Line Items]
Discrete adjustments to income tax expense recognized				$ 100,000

Acquisition - Additional Inform

Acquisition - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	May 31, 2017	Sep. 30, 2017
Noncash Or Part Noncash Acquisitions [Line Items]
Deferred tax assets		$ 22,200
Deferred tax liabilities		100
Deferred credit		$ 20,956
NephroGenex, Inc.
Noncash Or Part Noncash Acquisitions [Line Items]
Bankruptcy proceedings unsecured claim in exchange of common stock percentage	100.00%
Consideration paid	$ 1,200
Intangible assets	500
Deferred tax assets	22,200
Tax effected net operating losses	21,100
Tax effected net operating losses, valuation allowance	7,600
Tax effected capitalized research and development expenses	8,500
Tax effected federal tax credits	1,400
Tax effected federal tax credits, valuation allowance	1,200
Deferred tax liabilities	100
Deferred credit	$ 21,400

Net Income Per Share - Schedule

Net Income Per Share - Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Weighted-average shares:
Basic weighted-average common shares outstanding	38,579	37,118	39,803	34,138
Total weighted-average shares	38,641	37,118	39,863	34,138
Earnings per common share—Basic
Net income	$ 9,831	$ 5,036	$ 27,831	$ 13,446
Net income available to common shareholders—Basic	$ 9,815	$ 5,036	$ 27,789	$ 13,446
Net income per common share—Basic	$ 0.25	$ 0.14	$ 0.70	$ 0.39
Basic weighted-average common shares outstanding	38,579	37,118	39,803	34,138
Effect of diluted shares	750	505	734	227
Diluted weighted-average shares outstanding	39,329	37,623	40,537	34,365
Net income per common share—Diluted	$ 0.25	$ 0.13	$ 0.69	$ 0.39
RSAs
Weighted-average shares:
Basic weighted-average common shares outstanding	62	0	60	0
Earnings per common share—Basic
Less: Undistributed earnings allocated to RSAs	$ 16	$ 0	$ 42	$ 0
Basic weighted-average common shares outstanding	62	0	60	0
Common Stock
Weighted-average shares:
Basic weighted-average common shares outstanding	38,579	37,118	39,803	34,138
Earnings per common share—Basic
Basic weighted-average common shares outstanding	38,579	37,118	39,803	34,138

Net Income Per Share - Addition

Net Income Per Share - Additional Information (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted EPS	158,034	61,896	90,553	25,699
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted EPS	27,500		27,500	643,680

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair value measurements transfers between level 1, level 2, or level 3	$ 0	$ 0	$ 0	$ 0

Accounts Receivable And Unbil33

Accounts Receivable And Unbilled, Net - Schedule of Accounts Receivable and Unbilled, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accounts Notes And Loans Receivable Net Current [Abstract]
Accounts receivable	$ 50,973	$ 48,270
Unbilled	25,947	34,719
Less allowance for doubtful accounts	(2,212)	(3,222)
Total accounts receivable and unbilled, net	$ 74,708	$ 79,767

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Finite-lived intangible assets:
Total finite-lived intangible assets	$ 275,230	$ 274,661
Accumulated amortization:
Total accumulated amortization	(198,642)	(170,236)
Total finite-lived intangible assets, net	76,588	104,425
Trade name (indefinite-lived)	31,646	31,646
Total intangible assets, net	108,234	136,071
Backlog
Finite-lived intangible assets:
Total finite-lived intangible assets	72,630	72,630
Accumulated amortization:
Total accumulated amortization	(72,630)	(72,630)
Customer Relationships
Finite-lived intangible assets:
Total finite-lived intangible assets	145,051	145,051
Accumulated amortization:
Total accumulated amortization	(86,063)	(66,267)
Developed Technologies
Finite-lived intangible assets:
Total finite-lived intangible assets	54,475	54,475
Accumulated amortization:
Total accumulated amortization	(38,133)	(29,961)
Other
Finite-lived intangible assets:
Total finite-lived intangible assets	3,074	2,505
Accumulated amortization:
Total accumulated amortization	$ (1,816)	$ (1,378)

Intangible Assets, Net - Sche35

Intangible Assets, Net - Schedule of Estimated Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 9,495
2,018	29,561
2,019	14,828
2,020	7,877
2,021	5,114
Later years	9,713
Total finite-lived intangible assets, net	$ 76,588	$ 104,425

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued Liabilities And Other Liabilities [Abstract]
Employee compensation and benefits	$ 16,989	$ 21,453
Other	3,096	2,964
Total accrued expenses	$ 20,085	$ 24,417

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Debt	$ 185,719
Less unamortized discount	(432)	$ (534)
Less unamortized term loan debt issuance costs	(666)	(824)
Less current portion of long-term debt	(15,469)	(12,375)
Long-term debt, net, less current portion	169,152	151,267
Revolving credit facility
Debt Instrument [Line Items]
Debt	30,000
Term loan
Debt Instrument [Line Items]
Debt	$ 155,719	$ 165,000

Debt - Schedule of Principal Pa

Debt - Schedule of Principal Payments on Debt Due (Details) $ in Thousands	Sep. 30, 2017USD ($)
Debt Disclosure [Abstract]
2017 (remaining)	$ 3,094
2,018	16,500
2,019	16,500
2,020	20,625
2,021	129,000
Total	$ 185,719

Shareholder's Equity and Stoc39

Shareholder's Equity and Stock-Based Compensation - Additional Information (Details) - shares	Oct. 31, 2016	Sep. 30, 2017	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		818,896
2016 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards granted		974,896
Stock options granted			643,680
2016 Incentive Award Plan | Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted			626,650
Award vesting period			4 years
2016 Incentive Award Plan | Vesting After One Year | Non-employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		41,346
Award vesting period		1 year
2016 Incentive Award Plan | Vesting on October 31, 2016 and Eight equal monthly Installments
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted			17,030
Vesting percentage	33.00%
Award vesting description		stock options with one-third vesting on October 31, 2016, and the remainder vesting in eight equal monthly installments beginning in November 2016
2016 Incentive Award Plan | Stock Options | Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		777,550
Award vesting period		4 years
2016 Incentive Award Plan | Restricted Stock Awards (RSA) | Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period		4 years
Shares granted		118,000
2016 Incentive Award Plan | Restricted Stock Units (RSU) | Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period		4 years
Shares granted		38,000
2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards granted			45,923
2014 Equity Incentive Plan | Vesting Equally Over Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted			34,812
Award vesting period			4 years
2014 Equity Incentive Plan | Fully Vested Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted			11,111

Shareholder's Equity and Stoc40

Shareholder's Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Stock Options, Outstanding - beginning of period | shares	2,350,166
Number of Stock Options, Granted | shares	818,896
Number of Stock Options, Exercised | shares	(83,675)
Number of Stock Options, Forfeited/Expired | shares	(225,051)
Number of Stock Options, Outstanding - end of period | shares	2,860,336
Number of Stock Options, Exercisable - end of period | shares	939,835
Weighted average exercise price, Outstanding - beginning of period | $ / shares	$ 17.57
Weighted average exercise price, Granted | $ / shares	28.29
Weighted average exercise price, Exercised | $ / shares	15.26
Weighted average exercise price, Forfeited/Expired | $ / shares	20.66
Weighted average exercise price, Outstanding - end of period | $ / shares	20.46
Weighted average exercise price, Exercisable - end of period | $ / shares	$ 15.34

Shareholder's Equity and Stoc41

Shareholder's Equity and Stock-Based Compensation - Schedule of RSA/RSU Activity (Details) - RSA/RSU	9 Months Ended
	Sep. 30, 2017shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding and unvested - beginning of period	59,258
Granted	156,000
Vested	0
Forfeited	0
Outstanding and unvested - end of period	215,258
Cumulative vested shares - end of period	1,854,658

Shareholder's Equity and Stoc42

Shareholder's Equity and Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized in Statements of Operations Related to All Outstanding Stock Based Compensation Awards (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 981	$ 4,284	$ 3,215	$ 8,559
Direct Costs, Excluding Depreciation and Amortization
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	389	2,500	1,504	4,974
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 592	$ 1,784	$ 1,711	$ 3,585

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Effective income tax rate	35.10%	33.60%	35.70%	38.10%
U.S. statutory rate	35.00%		35.00%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Sep. 30, 2017USD ($)RenewalOptionAgreementBuilding	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)Parcel
Related Party Transaction [Line Items]
Service revenue with related parties	$ 2,000,000	$ 6,900,000		$ 8,900,000	$ 19,300,000
Reimbursed out-of-pocket revenue with related parties	200,000	1,400,000		1,300,000	4,300,000
Accounts receivable and unbilled, net	800,000			800,000		$ 2,300,000
Advanced billings	2,700,000			2,700,000		7,600,000
Pre-funded study costs with related parties	1,500,000			1,500,000		3,900,000
Deemed landlord liability, long-term portions	27,104,000			27,104,000		28,527,000
Cinven
Related Party Transaction [Line Items]
Director fees with related party				100,000
Management fees expense with related party					200,000
Cinven | Maximum
Related Party Transaction [Line Items]
Director fees with related party	100,000
Management fees expense with related party		100,000
Medpace Investors
Related Party Transaction [Line Items]
Related party tax expense		100,000			800,000
Employee Loans
Related Party Transaction [Line Items]
Employee advances receivables	200,000			200,000
Employee Loans | Other Assets
Related Party Transaction [Line Items]
Employee advances receivables						200,000
Service Agreements | Symplmed
Related Party Transaction [Line Items]
Negative service revenue adjustments		(400,000)
Service Agreements | Symplmed | Maximum
Related Party Transaction [Line Items]
Service revenue with related parties	100,000			100,000
Negative service revenue adjustments					(100,000)
Service Agreements | Coherus Bio Sciences Inc
Related Party Transaction [Line Items]
Service revenue with related parties	1,400,000	6,800,000		6,500,000	18,200,000
Reimbursed out-of-pocket revenue with related parties	100,000	1,300,000		1,100,000	4,200,000
Accounts receivable and unbilled, net	300,000			300,000		2,000,000
Advanced billings	2,600,000			2,600,000		6,300,000
Pre-funded study costs with related parties	1,500,000			1,500,000		3,800,000
Service Agreements | Xenon
Related Party Transaction [Line Items]
Service revenue with related parties		400,000	$ 600,000		800,000
Advanced billings						1,300,000
Pre-funded study costs with related parties						100,000
Service Agreements | Cymabay
Related Party Transaction [Line Items]
Service revenue with related parties	200,000	100,000		400,000	300,000
Service Agreements | LIB
Related Party Transaction [Line Items]
Service revenue with related parties	500,000	100,000		1,100,000	100,000
Accounts receivable and unbilled, net	200,000			200,000
Service Agreements | LIB | Maximum
Related Party Transaction [Line Items]
Accounts receivable and unbilled, net						$ 100,000
Service Agreements | CinRx
Related Party Transaction [Line Items]
Service revenue with related parties	100,000			300,000
Purchase of Real Estate Properties | Chief Executive Officer
Related Party Transaction [Line Items]
Number of parcel in real estate property | Parcel						4
Purchase price of real estate property				$ 400,000
Transaction closed date				Jan. 11, 2017
Leased Real Estate | Chief Executive Officer
Related Party Transaction [Line Items]
Term of lease				12 years
Lease expiration period				2022-11
Number of lease renewal, 10-year option | RenewalOption				1
Lease term upon renewal				10 years
Lease expense recognized	500,000	500,000		$ 1,600,000	1,600,000
Leased Real Estate | Chief Executive Officer And Immediate Family
Related Party Transaction [Line Items]
Term of lease				15 years
Number of lease renewal, 10-year option | RenewalOption				1
Lease term upon renewal				10 years
Number of lease agreements | Agreement				2
Number of buildings | Building				2
Lease occupancy year				2,012
Lease expiration year				2,027
Accretion expense paid	900,000	900,000		$ 2,800,000	2,800,000
Deemed landlord liability, current	1,800,000			1,800,000		$ 1,700,000
Deemed landlord liability, long-term portions	27,100,000			27,100,000		28,500,000
Leased Real Estate | Property and Equipment, Net | Chief Executive Officer And Immediate Family | Building
Related Party Transaction [Line Items]
Deemed assets, net	16,800,000			16,800,000		$ 18,100,000
Travel Services | Chief Executive Officer
Related Party Transaction [Line Items]
Travel expenses with related party	$ 300,000	$ 300,000		$ 900,000	$ 800,000

Cash Flow Statement- Suppleme45

Cash Flow Statement- Supplemental Information - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)
Supplemental Cash Flow Information [Abstract]
Acquisition of net assets	$ 0.7
Deferred tax assets, net	22.2
Deferred tax liabilities, net	0.1
Deferred credits	21.4
Accounts receivable and unbilled, net	0.6
Other assets	$ 0.1